Company profile NUVB
There is not enough data for Nuvation Bio - Oncology therapeutics to provide analysis
There is not enough data for Nuvation Bio - Oncology therapeutics to provide correlation calculation
There is not enough data for Nuvation Bio - Oncology therapeutics to provide analysis
There is not enough data for NUV-868 to provide analysis
There is not enough data for NUV-868 to provide correlation calculation
There is not enough data for NUV-868 to provide analysis
There is not enough data for Oral small molecule BET inhibitor to provide analysis
There is not enough data for Oral small molecule BET inhibitor to provide correlation calculation
There is not enough data for Oral small molecule BET inhibitor to provide analysis
There is not enough data for Tumor growth regulation to provide analysis
There is not enough data for Tumor growth regulation to provide correlation calculation
There is not enough data for Tumor growth regulation to provide analysis
There is not enough data for NUV-1156 to provide analysis
There is not enough data for NUV-1156 to provide correlation calculation
There is not enough data for NUV-1156 to provide analysis
There is not enough data for AR binder Xtandi to provide analysis
There is not enough data for AR binder Xtandi to provide correlation calculation
There is not enough data for AR binder Xtandi to provide analysis
After 39 days of this quarter the interest is at 369.0. Based on that we can calculate that during remaining 52 days it will total up to 861.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 492 | 791 60.8% QoQ | 778 -1.6% QoQ | 836 7.5% QoQ |
| 2020 | 808 64.2% YoY -3.3% QoQ | 630 -20.4% YoY -22.0% QoQ | 792 1.8% YoY 25.7% QoQ | 808 -3.3% YoY 2.0% QoQ |
| 2021 | 759 -6.1% YoY -6.1% QoQ | 890 41.3% YoY 17.3% QoQ | 1018 28.5% YoY 14.4% QoQ | 969 19.9% YoY -4.8% QoQ |
| 2022 | 837 10.3% YoY -13.6% QoQ | 791 -11.1% YoY -5.5% QoQ | 828 -18.7% YoY 4.7% QoQ | 790 -18.5% YoY -4.6% QoQ |
| 2023 | 895 6.9% YoY 13.3% QoQ | 872 10.2% YoY -2.6% QoQ | 815 -1.6% YoY -6.5% QoQ | 868 9.9% YoY 6.5% QoQ |
| 2024 | 369 -58.8% YoY -57.5% QoQ | - | - | - |
The average 5 years interest of Prostate cancer treatment was 63.74 per week. The last year interest of Prostate cancer treatment compared to the last 5 years has changed by 3.03%. The interest for Prostate cancer treatment is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by 5.32%.
There is not enough data for Surgical prostatectomy to provide analysis
There is not enough data for Surgical prostatectomy to provide correlation calculation
There is not enough data for Surgical prostatectomy to provide analysis
There is not enough data for Drug-drug conjugate (DDC) platform to provide analysis
There is not enough data for Drug-drug conjugate (DDC) platform to provide correlation calculation
There is not enough data for Drug-drug conjugate (DDC) platform to provide analysis
After 39 days of this quarter the interest is at 138.0. Based on that we can calculate that during remaining 52 days it will total up to 322.0. PARP inhibitor expected interest is significantly lower compared to previous quarter (-45.0%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 408 | 632 54.9% QoQ | 570 -9.8% QoQ | 526 -7.7% QoQ |
| 2020 | 605 48.3% YoY 15.0% QoQ | 534 -15.5% YoY -11.7% QoQ | 485 -14.9% YoY -9.2% QoQ | 502 -4.6% YoY 3.5% QoQ |
| 2021 | 499 -17.5% YoY -0.6% QoQ | 573 7.3% YoY 14.8% QoQ | 465 -4.1% YoY -18.8% QoQ | 443 -11.8% YoY -4.7% QoQ |
| 2022 | 621 24.4% YoY 40.2% QoQ | 566 -1.2% YoY -8.9% QoQ | 534 14.8% YoY -5.7% QoQ | 559 26.2% YoY 4.7% QoQ |
| 2023 | 533 -14.2% YoY -4.7% QoQ | 506 -10.6% YoY -5.1% QoQ | 545 2.1% YoY 7.7% QoQ | 585 4.7% YoY 7.3% QoQ |
| 2024 | 138 -74.1% YoY -76.4% QoQ | - | - | - |
The average 5 years interest of PARP inhibitor was 41.49 per week. The last year interest of PARP inhibitor compared to the last 5 years has changed by -5.3%. The interest for PARP inhibitor is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -13.42%.
Google Trends for ER+ breast and ovarian cancer treatment
Not enough data for reliable calculations!
There is not enough data for ER+ breast and ovarian cancer treatment to provide analysis
There is not enough data for ER+ breast and ovarian cancer treatment to provide correlation calculation
There is not enough data for ER+ breast and ovarian cancer treatment to provide analysis
There is not enough data for Biopharmaceutical development. to provide analysis
There is not enough data for Biopharmaceutical development. to provide correlation calculation
There is not enough data for Biopharmaceutical development. to provide analysis